Superior Nano LLC received a $512,000 National Science Foundation Project Grant to develop dense nanolipid fluid systems for delivering drugs with poor bioavailability. The NSF funding supports research from June 2022 to May 2023 under the Technology, Innovation, and Partnerships program. This award will allow Superior Nano to advance scientific understanding of surfactant-lipid-water systems and create new knowledge applicable to manufacturing drug nanoparticles using twin-screw extrusion. By...
This SBIR Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $275,000 to Delaqua Pharmaceuticals, Inc. to develop a polymeric micelle platform for enhancing the solubility and stability of hydrophobic drugs. The objectives are to improve the formulation of the micelles, perform initial toxicity studies, and demonstrate efficacy for solubilizing different drug classes. This research aims to improve the...
This $274,990 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) supports the development of a physics-based machine learning platform for predicting the crystal structure of small drug molecules. The technology aims to accelerate and reduce the cost of early-stage pharmaceutical research and development by computationally analyzing the crystal structure properties that determine key...
Nano Pharmasolutions, Inc. received a $275,961 Project Grant award from the National Science Foundation Division of Industrial Innovation under the Engineering federal grant program (CFDA 47.041). The grant funds the development of a novel nanoformulation drug delivery platform to address challenges associated with poorly soluble drugs. The goal is to improve drug solubility and bioavailability through innovative formulation approaches. The one-year project period runs from August 1, 2021...
Nostopharma LLC was awarded a $256,000 Small Business Technology Transfer Phase I Project Grant from the National Science Foundation to develop a sustained-release, biodegradable nanoparticle drug delivery system for treatment of soft tissue trauma complications. Funded under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084), the 12-month project beginning March 1, 2022 aims to demonstrate in vitro and in vivo feasibility of modulating the ectopic bone microenvironment...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) Program (CFDA 47.084) Project Grant award of $275,000 provides funding to Illuminate Therapeutics, Inc. to develop their Light Activated Drug Delivery and Release (LADDR) platform technology. The objective is to improve patient outcomes in the treatment of head and neck and esophageal cancers, which represent a combined market of over $2.34B in 2021 growing at 10.5% annually. The key focus of this SBIR Phase...
The National Science Foundation awarded Diant Pharma Inc. a $256,000 Project Grant under the Engineering (47.041) federal grant program. The grant will support development of an advanced continuous manufacturing system for nucleic acid lipid nanoparticles to improve supply chains for therapeutics and vaccines. Specifically, the small business innovation research Phase I project aims to create a compact, end-to-end manufacturing platform that follows current good manufacturing practices. This...
Spirrow Therapeutics LLC received a $256,000 Small Business Technology Transfer (STTR) Phase I Project Grant from the National Science Foundation under the Engineering program (CFDA 47.041) to develop polymer surfactant therapy for acute respiratory distress syndrome (ARDS), including that caused by COVID-19. The grant period runs from February 15, 2021 through January 31, 2022. The NSF Engineering program seeks to improve quality of life and economic strength through engineering research and...
Biosapien Inc. received a $256,000 Project Grant award from the National Science Foundation on May 1, 2021 to develop a novel 3D printed biodegradable mesh delivering active pharmaceutical ingredients in a sustained and localized manner under the Small Business Innovation Research Phase I program. The SBIR Phase I grant supports the proof-of-concept stage of developing Biosapien's technology, with the work expected to be completed by June 30, 2022. The NSF Technology, Innovation, and...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) award of $274,947 to Lattice Therapeutics Inc. supports the development of a customizable, next-generation RNA delivery particle. The project aims to validate the ability of an engineerable protein nanoparticle platform to efficiently and specifically deliver RNA cargoes to target cancer cells. Key objectives include in vitro evaluation of RNA...